Richard Heyman Sells 1,230 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 1,230 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $32,902.50. Following the sale, the director owned 23,877 shares in the company, valued at approximately $638,709.75. The trade was a 4.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Enliven Therapeutics Trading Down 0.6%

NASDAQ ELVN traded down $0.17 on Thursday, hitting $27.03. 1,466,778 shares of the company’s stock traded hands, compared to its average volume of 1,935,634. The firm’s 50-day moving average price is $20.22 and its two-hundred day moving average price is $20.27. The firm has a market capitalization of $1.60 billion, a PE ratio of -14.69 and a beta of 0.41. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ELVN shares. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ELVN. Commodore Capital LP raised its position in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Polar Capital Holdings Plc grew its position in Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after purchasing an additional 44,713 shares during the last quarter. Vanguard Group Inc. increased its stake in Enliven Therapeutics by 5.9% in the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after purchasing an additional 142,378 shares during the period. Vestal Point Capital LP raised its holdings in shares of Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after buying an additional 910,000 shares during the last quarter. Finally, Duquesne Family Office LLC grew its holdings in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.